Bioxytran (OTC: BIXT) has announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million.
In connection with the financing, the company issued approximately 21,071,667 common shares at $0.055 per share. Investors also received five-year warrants to purchase up to 19,750,001 additional shares at an exercise price of $0.12 per share.
In a statement, David Platt, PhD, CEO of Bioxytran, commented, “This financing strengthens our balance sheet and supports the advancement of our clinical and development initiatives. In parallel, we are beginning to translate our galectin-targeting platform into commercial opportunities, including the market introduction of A-SUQAR, our plant-derived dietary supplement expected to launch this quarter. This dual-track approach allows us to pursue near-term commercialization while continuing to advance our higher-value pharmaceutical programs.”
